الفهرس 
Definition and Immunology of Multiple SclerosisOnly 14 pages are availabe for public view
 |  | from | 32 |  |  |
| | | from | 32 | | |
Abstract
The relationship between IL-10 as an anti-inflammatory cytokine in MS has been investigated in few studies. This pilot study aimed to verify a possible relationship between IL-10 and the drugs used for treatment of MS. The effects of IFNs as approved disease modifying drugs for MS and CYC as an off-label drug on the serum levels of IL-10 were investigated.
This study included 3 groups; a group of 20 RRMS patients who had been receiving IFN-β, a group of 20 RRMS patients who had been receiving CYC and a control group that included 20 healthy age and sex matched individuals. Serum samples for measuring the levels of IL-10 were obtained from all of them.
All of the groups were compared with no statistical differences regarding the age, sex and clinical features of the disease such as the duration of disease, total number of relapses, the number of relapses on treatment, the duration that the patient had been receiving either treatment, or the presence of MRI lesions.
Analysis of the laboratory data showed that the serum levels of IL-10 were significantly higher in IFN and CYC groups compared to the control group (P=0.044 and P<0.001 respectively). When IFN group was compared to CYC group, IL-10 levels were higher among the CYC group (P=0.005).